Drugs / SRM003
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT01806584 Comparator | Mar 2013 → Oct 2014 | — | Shire | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT01806545 Comparator | Mar 2013 → Oct 2014 | — | Shire | Completed | No outcome recorded |
Press releases naming this drug 1 release
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SRM003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01806545 ↗ |
| Known as | Vascugel | “A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in the Treatment of Subjects With Vascular Injury...” NCT01806584 ↗ |
| Modality | Cell therapy | “the seeded SRM003 gelatin matrix containing endothelial cells” NCT01806545 ↗ |
| Route | Other | “One time implant (2 SRM003 pieces) on surgery day.” NCT01806545 ↗ |